ホーム>>Natural Products>>Dehydroandrographolide succinate potassium sodium salt

Dehydroandrographolide succinate potassium sodium salt

カタログ番号GC35831

コハク酸デヒドロアンドログラフォライド (カリウム ナトリウム塩) は、漢方薬 Andrographis paniculata (Burm f) Nees から抽出され、その免疫刺激、抗感染および抗炎症効果により、ウイルス性肺炎およびウイルス性上気道感染症の治療に広く使用されています [1 ]。

Products are for research use only. Not for human use. We do not sell to patients.

Dehydroandrographolide succinate potassium sodium salt 化学構造

Cas No.: 863319-40-8

サイズ 価格 在庫数 個数
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Dehydroandrographolide succinate (potassium sodium salt), extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used for the treatment of viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect[1][2].

[1]. Chen Q, et al. Pharmacokinetics and tolerance of dehydroandrographolide succinate injection after intravenousadministration in healthy Chinese volunteers. Acta Pharmacol Sin. 2012 Oct;33(10):1332-6. [2]. Xiaomeng Z, et al. Potassium dehydroandrographolide succinate injection for treat- ment of infantile pneumonia: a systematic review and Meta-analysis. J Tradit Chin Med. 2015 Apr;35(2):125-33.

レビュー

Review for Dehydroandrographolide succinate potassium sodium salt

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Dehydroandrographolide succinate potassium sodium salt

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.